SPY457.40+6.90 1.53%
DIA346.61+6.15 1.81%
IXIC15,381.32+127.27 0.83%

SVB Leerink Maintains Outperform on Harpoon Therapeutics, Lowers Price Target to $19

SVB Leerink analyst Jonathan Chang maintains Harpoon Therapeutics (NASDAQ:HARP) with a Outperform and lowers the price target from $25 to $19.

Benzinga · 11/11/2021 05:03
SVB Leerink analyst Jonathan Chang maintains Harpoon Therapeutics (NASDAQ:HARP) with a Outperform and lowers the price target from $25 to $19.